8-K: Cerus Corp Reports Strong Q1 2025, Product Revenue Up 13% and Reaffirms Full-Year Guidance

Cerus Corporation announces a 13% increase in first-quarter product revenue and reiterates its full-year revenue guidance of $194-$200 million.

Summary

• Cerus Corporation announced its financial results for the first quarter ended March 31, 2025.
• First quarter product revenue increased by 13% year-over-year to $43.2 million.
• Total revenue for the first quarter was $48.9 million, including $5.6 million from government contracts.
• The company reiterated its full-year 2025 product revenue guidance of $194 million to $200 million.
• Adoption of INTERCEPT Fibrinogen Complex (IFC) continues to increase, with first quarter 2025 IFC revenue of $3.0 million compared to $1.9 million in the prior year period.
• The company received CE mark for the INT200, its next-generation, LED-based illumination device.
• An updated CE Mark application for the INTERCEPT red blood cell system has been submitted.
• Cash, cash equivalents, and short-term investments totaled $80.9 million as of March 31, 2025.
• The company aims to achieve positive, full-year 2025 non-GAAP adjusted EBITDA.
• Net loss attributable to Cerus Corporation for the first quarter of 2025 was $7.7 million, or $0.04 per basic and diluted share.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability metrics, and successful product development milestones. While there are some challenges, the overall tone is optimistic and suggests a promising future for the company.

Positives

• Product revenue increased by 13% year-over-year in the first quarter of 2025.
• North American product revenue showed robust growth of 22%.
• IFC revenue increased significantly, indicating growing adoption.
• The company received CE mark for the INT200 ahead of schedule.
• Gross margin increased to 58.8% compared to 55.4% for the same period of the prior year.
• Non-GAAP adjusted EBITDA turned positive in Q1 2025.
• The company is reiterating its full-year 2025 product revenue guidance.
• The company believes it is in a position to deliver operating cash flow to fuel growth and make INTERCEPT the standard of care for blood safety globally.

Negatives

• EMEA revenue declined by 4%, largely due to foreign currency exchange rates.
• Total operating expenses increased by 8% year-over-year.
• Cash use from operations totaled $0.8 million compared to $2.0 million generated during the same period of the prior year.
• Net loss attributable to Cerus Corporation for the first quarter of 2025 was $7.7 million, or $0.04 per basic and diluted share.

Risks

• Commercialization and market acceptance of the INTERCEPT Blood System may not meet expectations.
• Macroeconomic developments, including military conflict in Ukraine and trade tensions, could negatively impact business operations and financial results.
• The company faces risks related to its lack of longer-term commercialization experience with the INTERCEPT Blood System for Cryoprecipitation and in the United States generally.
• Future platelet additive solution (PAS) supply disruptions could affect INTERCEPT's acceptance in the marketplace.
• The development and regulatory process is uncertain and time-consuming.
• The company relies on third parties to market, sell, distribute and maintain its products.
• The company's supply chain could be negatively impacted as a result of the evolving impact of macroeconomic developments.
• The company's ability to access additional funds under its credit facility and to meet its debt service obligations, and its need for additional funding.

Future Outlook

Cerus expects full-year 2025 product revenue to be in the range of $194 million to $200 million, reflecting 8% to 11% growth from 2024, and aims to achieve positive, full-year 2025 non-GAAP adjusted EBITDA.

Management Comments

• William Obi Greenman, Cerus president and chief executive officer, stated that the company is off to a strong start in 2025, executing against its stated goals and making meaningful progress in advancing Cerus' mission.
• Greenman believes the company is in a position to deliver operating cash flow to fuel its growth and make INTERCEPT the standard of care for blood safety globally.

Industry Context

Cerus operates in the blood transfusion safety market, where pathogen reduction technologies are increasingly important. The company's focus on innovation, such as the INT200 and the INTERCEPT red blood cell system, positions it to compete effectively in this space. Increased adoption of INTERCEPT Fibrinogen Complex (IFC) reflects a growing awareness of the importance of fibrinogen deficiency management in bleeding control.

Comparison to Industry Standards

• Cerus's 13% product revenue growth in Q1 2025 is a solid performance compared to other companies in the medical device and blood transfusion industry.
• Companies like Haemonetics (HAE), which also operates in the blood management sector, have seen varying growth rates depending on their specific product lines and market segments.
• Terumo BCT, another key player, focuses on blood component and cellular technologies, and their growth is influenced by global healthcare trends and regulatory approvals.
• The CE Mark for INT200 is a significant achievement, placing Cerus ahead of competitors who may not have similar next-generation illumination devices approved in Europe.
• The company's focus on achieving positive non-GAAP adjusted EBITDA for the full year 2025 aligns with industry expectations for sustainable profitability.

Stakeholder Impact

• Shareholders: Positive results and future outlook may increase shareholder value.
• Employees: Investments in the business and cost of living adjustments may improve employee morale.
• Customers: Continued innovation and product availability may enhance customer satisfaction.
• Patients: Improved blood safety and availability may benefit patients relying on transfusions.

Next Steps

• Continue commercialization and market penetration of the INTERCEPT Blood System.
• Increase IFC supply to meet growing customer demand.
• Obtain CE Mark for the INTERCEPT red blood cell system.
• Advance pipeline programs and bring them to market.
• Expand commercialization activities, including of the INT200, into additional geographies.

Key Dates

Keywords

Cerus Corporation, INTERCEPT Blood System, Product Revenue, Financial Results, CE Mark, IFC, INT200, EBITDA, Blood Safety, Pathogen Reduction